Table 4 Subgroup analysis of the cell viability of CAP and DOX combination in melanoma based on the type of cell line, gas and treatment time.
Treatment | Group | Subgroup | Viability_I2 | Viability_ ES |
|---|---|---|---|---|
CAP | Cell line | B16F10 | 70.3 | 48.43 |
B16F0 | 0 | 72.96 | ||
A375 | 98 | 1.54 | ||
SK-Mel-28 | 72 | 52.23 | ||
Gas | Helium | 88.5 | 55.50 | |
Argon | 94.9 | 59.38 | ||
DOX | Cell line | B16F10 | 87.7 | 12.18 |
A375 | 86.6 | 13.63 | ||
SK-Mel-28 | 0 | 17.17 | ||
Treat-time | 48Â h | 0 | 25.92 | |
24Â h | 85.8 | 29.09 | ||
6Â h | 0 | 40.80 |
CAP-DOX treatment | Subgroup | Viability_I2 | Viability_ ES | |
|---|---|---|---|---|
Cell line | B16F10 | 83.7 | 17.76 | |
B16F0 | 0 | 7.90 | ||
A375 | 0 | 1.20 | ||
SK-Mel-28 | 0 | 13.52 | ||
Gas | Helium | 82.0 | 16.09 | |
Argon | 23.3 | 5.71 | ||
Treat-time (h) | 48 | 18.8 | 25.49 | |
24 | 0 | 1.20 | ||
6 | 23.3 | 5.71 | ||
